AEON Biopharma, Inc. — Form 8-K Summary
Business context and reporting period
AEON Biopharma, Inc. filed a Form 8-K under Item 4.02 on May 3, 2024, reporting that its previously issued financial statements should no longer be relied upon. The Board reached this conclusion on May 1, 2024. The affected periods are the three and nine months ended September 30, 2023, and the year ended December 31, 2023.
Financial impact and material changes
- The error relates to the accounting for acquired in-process research and development, or IPR&D, recorded in connection with the Merger.
- The IPR&D should have been recorded on the Successor’s opening balance sheet and subsequently written off through the consolidated statement of operations and comprehensive loss.
- The correction is expected to increase reported net loss for the Successor periods from July 22, 2023 through September 30, 2023 and December 31, 2023 by $348.0 million.
- The correction is non-cash and had no impact on cash balances or operating cash flows for the quarter ended September 30, 2023 or the year ended December 31, 2023.
- The filing does not provide revised revenue, margins, liquidity balances, debt, or cash-flow amounts.
Restatement, controls, outlook, and risks
- AEON expects to file restated audited consolidated financial statements for the year ended December 31, 2023 and restated interim financial statements for the periods ended September 30, 2023 in an amendment to its Form 10-K.
- The Company expects to report an additional material weakness related to the accounting error, in addition to previously disclosed internal-control weaknesses, including weaknesses associated with Priveterra.
- Management and the Board discussed the matter with KPMG LLP, the Company’s independent registered public accounting firm.
- AEON expects to continue reporting substantial doubt about its ability to continue as a going concern for the twelve months from the dates of the amended filings. It also anticipates disclosing substantial doubt regarding liquidity for at least twelve months from the expected issuance of its Form 10-Q for the quarter ended March 31, 2024.
- Key risks include potential legal proceedings, continued compliance with stock-exchange listing standards, public-company costs, liquidity constraints, and other risks disclosed in SEC filings.
Important facts for investors to verify
- Review the amended Form 10-K and restated financial statements when filed, including the precise effect of the $348.0 million correction on assets, accumulated deficit, net loss, and per-share amounts.
- Assess the Company’s updated cash position, financing plans, liquidity, and going-concern disclosures in the forthcoming Form 10-Q and amended filings.
- Review management’s remediation plan and auditor disclosures concerning the material weaknesses.
- Confirm whether the Company remains compliant with NYSE American listing standards and monitor any related legal or regulatory developments.